Filing Flows › Alkermes (ALKS) › Q1 2025
Alkermes (ALKS) Q1 2025 earnings results (first quarter 2025)
10-Q filed May 1, 2025
Alkermes (ALKS) reported revenue of $307M for the first quarter 2025 (Q1 2025), -13% from a year earlier and -29% from the quarter before. Operating margin was 4.5%, net earnings $22.5M (7.3% of revenue).
Alkermes, Q1 2025: revenue $307M (-12% year over year), operating margin 4.5%, net earnings $22.5M, operating cash flow $98.8M. The chart follows the revenue to costs, profit and cash.
| Q1 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $307M | -29% | -13% |
| Operating profit | $13.8M | -92% | -68% |
| Net earnings | $22.5M | -85% | -39% |
| Operating cash flow | $98.8M | -48% | +368% |
| Free cash flow | $88.7M | -51% | +595% |
What changed
Revenue was $306.5M in Q1 2025, down 13% year over year and down 29% from the previous quarter. Vivitrol was the largest line at 33% of revenue. Royalty lost $42.1M year over year (down 49%), 96% of the total change.
Operating profit was $13.8M, a 4.5% margin (down 7.9 points year over year). Total costs fell 5% while revenue fell 13%. Net earnings were $22.5M, down 39% year over year. The effective tax rate was 11.9%. Non-operating items added $11.7M, 46% of pre-tax earnings, so the bottom line overstates operating performance.
Operating cash flow was $98.8M (up 368% year over year), 440% of net earnings. Non-cash charges added back $7.4M of depreciation and amortization and $22.8M of share-based compensation. Working capital and other items added $46.1M. Capital expenditures of $10.1M left free cash flow of $88.7M.
Questions
What was Alkermes' revenue in the first quarter 2025?
Alkermes (ALKS) reported revenue of $307M for the first quarter 2025 (Q1 2025), -13% from a year earlier and -29% from the quarter before.
Was Alkermes profitable in the first quarter 2025?
Operating profit was $13.8M (4.5% of revenue) and net earnings $22.5M.
Source: Alkermes 10-Q on SEC EDGAR.